BACTROBAN

This brand name is authorized in Australia, Austria, Brazil, Cyprus, Estonia, Finland, France, Hong Kong SAR China, Ireland, Israel, Japan, Malta, Mexico, New Zealand, Poland, Singapore, South Africa, Spain, Tunisia, Turkey, UK.

Active ingredients

The drug BACTROBAN contains one active pharmaceutical ingredient (API):

1	Mupirocin UNII RG38I2P540 - MUPIROCIN CALCIUM
	Mupirocin is a novel antibiotic produced through fermentation by Pseudomonas fluorescens. Mupirocin inhibits isoleucyl transfer-RNA synthetase, thereby arresting bacterial protein synthesis. Mupirocin has bacteriostatic properties at minimum inhibitory concentrations and bactericidal properties at the higher concentrations reached when applied locally.
	Read more about Mupirocin

Medication package inserts

Below package inserts are available for further reading:

Document	Type	Information Source
BACTROBAN 2% Cream	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)
BACTROBAN Nasal ointment	MPI, EU: SmPC	Medicines & Healthcare Products Regulatory Agency (GB)

Medicine classification

This drug has been classified in the anatomical therapeutic chemical (ATC) classification system as follows:

ATC Group		Classification
D06AX09	Mupirocin	D Dermatologicals → D06 Antibiotics and chemotherapeutics for dermatological use → D06A Antibiotics for topical use → D06AX Other antibiotics for topical use
Discover more medicines within D06AX09
R01AX06	Mupirocin	R Respiratory system → R01 Nasal preparations → R01A Decongestants and other nasal preparations for topical use → R01AX Other nasal preparations
Discover more medicines within R01AX06

Authorization and marketing

This drug has been assigned below unique identifiers within the countries it is being marketed:

Country	Identification scheme	Identifier(s)
AU	Pharmaceutical Benefits Scheme	4348W, 4350Y, 9440W
BR	Câmara de Regulação do Mercado de Medicamentos	510601301160316, 510614020051403
EE	Ravimiamet	1110283, 1272743, 1865224
ES	Centro de información online de medicamentos de la AEMPS	58868, 59531
FI	Lääkealan turvallisuus- ja kehittämiskeskus	545681, 568709
FR	Base de données publique des médicaments	66325311
GB	Medicines & Healthcare Products Regulatory Agency	138358, 142019, 142021, 161401, 165417, 165419, 29069, 29081, 29085
HK	Department of Health Drug Office	28186, 33588
IE	Health Products Regulatory Authority	13716, 13765, 13773, 36830
IL	מִשְׂרַד הַבְּרִיאוּת	976, 977
JP	医薬品医療機器総合機構	6119700M1035
MT	Medicines Authority	MA192/02401, MA192/02402, MA192/02403, PI908/10601A
MX	Comisión Federal para la Protección contra Riesgos Sanitarios	037M86
NL	Z-Index G-Standaard	13250728, 13577395
NL	Z-Index G-Standaard, PRK	21156, 32085
NZ	Medicines and Medical Devices Safety Authority	4227
PL	Rejestru Produktów Leczniczych	100008702, 100008719, 100098125, 100162952, 100241723, 100241746, 100272221, 100298717, 100298976, 100304398, 100324484, 100366146, 100384865, 100384888, 100394177, 100396816, 100399051, 100405053, 100421595, 100425185, 100427563, 100431820, 100437202, 100443740, 100459033, 100460327
SG	Health Sciences Authority	00554P, 05075P, 11204P
TN	Direction de la Pharmacie et du Médicament	5143011
TR	İlaç ve Tıbbi Cihaz Kurumu	8699522355426, 8699522358014, 8699522385522, 8699522385539
ZA	Health Products Regulatory Authority	34/20.1.6/0274, T/20.1.6/0075, W/20.1.6/218